c peptide Search Results


94
Miltenyi Biotec insulin
Insulin, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/insulin/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
insulin - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

94
Thermo Fisher 3×dykddddk peptides
3×Dykddddk Peptides, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/3×dykddddk peptides/product/Thermo Fisher
Average 94 stars, based on 1 article reviews
3×dykddddk peptides - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

92
Monobind c peptide
C Peptide, supplied by Monobind, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/c peptide/product/Monobind
Average 92 stars, based on 1 article reviews
c peptide - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier

93
Thermo Fisher quantitative colorimetric peptide assay
Quantitative Colorimetric Peptide Assay, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/quantitative colorimetric peptide assay/product/Thermo Fisher
Average 93 stars, based on 1 article reviews
quantitative colorimetric peptide assay - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

95
Chem Impex International glycerol chem impex
Glycerol Chem Impex, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/glycerol chem impex/product/Chem Impex International
Average 95 stars, based on 1 article reviews
glycerol chem impex - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier

95
TaKaRa sandwich enzyme linked 39mmune sorbant assay elisa
Sandwich Enzyme Linked 39mmune Sorbant Assay Elisa, supplied by TaKaRa, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sandwich enzyme linked 39mmune sorbant assay elisa/product/TaKaRa
Average 95 stars, based on 1 article reviews
sandwich enzyme linked 39mmune sorbant assay elisa - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier

94
Shanghai Korain Biotech Co Ltd e0089hu
E0089hu, supplied by Shanghai Korain Biotech Co Ltd, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/e0089hu/product/Shanghai Korain Biotech Co Ltd
Average 94 stars, based on 1 article reviews
e0089hu - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

91
Boster Bio cxcl5 level
Fig. 6 An increase in levels of acetyl-CoA and H3K27ac promotes <t>CXCL5</t> secretion in CAFs. The effects of acetate treatment on acetyl-CoA levels in LX-2 cells incubated with ExoHCT116 (A) and ExoSW480 (B). Western blot showed the effects of acetate treatment on CXCL5 and H3K27ac levels in LX-2 cells incubated with ExoHCT116 (C) and ExoSW480 (D). E The effects of Trichostatin A (TSA) treatment on CXCL5 and H3K27ac levels in LX-2 cells incubated with ExoHCT116 KD and their relative control. F The effects of C646 treatment on CXCL5 and H3K27ac levels in LX-2 cells incubated with ExoSW480 OE and their relative control. G, H Chromatin immunoprecipitation (ChIP) assays using IgG as a control were performed with antibody against H3K23ac. Examination of H3K27 acetylation status in CXCL5 gene promoter region in LX-2 cells incubated with ExoHCT116 KD and ExoHCT116 KD Ctrl or in LX-2 cells incubated with ExoHCT116 KD and ExoHCT116 KD Ctrl and treated with TSA (G). Examination of H3K27 acetylation status in CXCL5 gene promoter region in LX-2 cells incubated with ExoSW480 OE and ExoSW480 OE Ctrl or in LX- 2 cells incubated with ExoSW480 OE and ExoSW480 OE Ctrl and treated with C646 (H). Each experiment was performed in triplicate. Data are shown as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.
Cxcl5 Level, supplied by Boster Bio, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cxcl5 level/product/Boster Bio
Average 91 stars, based on 1 article reviews
cxcl5 level - by Bioz Stars, 2026-02
91/100 stars
  Buy from Supplier

96
ALPCO human c peptide kit
Fig. 6 An increase in levels of acetyl-CoA and H3K27ac promotes <t>CXCL5</t> secretion in CAFs. The effects of acetate treatment on acetyl-CoA levels in LX-2 cells incubated with ExoHCT116 (A) and ExoSW480 (B). Western blot showed the effects of acetate treatment on CXCL5 and H3K27ac levels in LX-2 cells incubated with ExoHCT116 (C) and ExoSW480 (D). E The effects of Trichostatin A (TSA) treatment on CXCL5 and H3K27ac levels in LX-2 cells incubated with ExoHCT116 KD and their relative control. F The effects of C646 treatment on CXCL5 and H3K27ac levels in LX-2 cells incubated with ExoSW480 OE and their relative control. G, H Chromatin immunoprecipitation (ChIP) assays using IgG as a control were performed with antibody against H3K23ac. Examination of H3K27 acetylation status in CXCL5 gene promoter region in LX-2 cells incubated with ExoHCT116 KD and ExoHCT116 KD Ctrl or in LX-2 cells incubated with ExoHCT116 KD and ExoHCT116 KD Ctrl and treated with TSA (G). Examination of H3K27 acetylation status in CXCL5 gene promoter region in LX-2 cells incubated with ExoSW480 OE and ExoSW480 OE Ctrl or in LX- 2 cells incubated with ExoSW480 OE and ExoSW480 OE Ctrl and treated with C646 (H). Each experiment was performed in triplicate. Data are shown as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.
Human C Peptide Kit, supplied by ALPCO, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human c peptide kit/product/ALPCO
Average 96 stars, based on 1 article reviews
human c peptide kit - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier

90
MedChemExpress recombinant npy protein
Osteocyte <t>NPY‐induced</t> BMSC fate switching is mediated by the inhibition of TEAD1 and JUNB through cAMP/PKA/CREB signaling. qRT‐PCR analysis of Tead1 and Junb expression in BMSCs receiving different treatments under A) osteogenic or B) adipogenic induction for 24 h, or C) in undifferentiated BMSCs with different treatments for 24 h. n = 3 per group. D) qRT‐PCR and E) western blotting confirmed the overexpression efficiency of <t>recombinant</t> Tead1 and Junb lentiviruses in BMSCs. n = 3 per group. F) ARS and ORO staining images and G) quantification of the positively stained areas showing the reduced activity of NPY to inhibit osteogenesis and promote adipogenesis of BMSCs overexpressing Tead1 or Junb . Scale bar: 50 µm. n = 3 per group. ELISA for cAMP in BMSCs receiving different treatments under H) osteogenic or I) adipogenic induction for 24 h. n = 3 per group. PKA activity assay for cell homogenates of BMSCs receiving different treatments under J) osteogenic or K) adipogenic induction for 24 h. n = 3 per group. L) Western blotting for CREB and phosphorylated CREB (p‐CREB) in BMSCs receiving different treatments under osteogenic or adipogenic induction for 24 h. qRT‐PCR analysis of M) Tead1 and N) Junb expression in BMSCs receiving different treatments under osteogenic induction for 24 h. n = 3 per group. O) ARS and ORO staining images and P) quantification of the positively stained areas in BMSCs receiving different treatments under osteogenic or adipogenic induction. Scale bar: 50 µm. n = 3 per group. Q) ChIP‐qRT‐PCR analysis shows enrichment of the CREB antibody (CREB Ab)‐immunoprecipitated Tead1 or Junb promoter region relative to the input DNA. Normal rabbit anti‐IgG served as a negative control. Histone H3 antibody (Histone H3 Ab) pulldown for the enrichment of Rpl30 gene served as a positive control. n = 3 per group. Data are presented as mean ± SD. For panels (A), (B), (G), (H–K), (M), (N), and (P): unpaired, two‐tailed student's t ‐test (differences between un‐induced and control groups in (A), (B), and (H–K), or between control and NPY groups in (G), (M), (N), and (P)) or one‐way ANOVA combined with Bonferroni post hoc test (differences among other groups except un‐induced group in (A), (B), and (H–K), or except control group in (M), (N), and (P)). For panel (C) and (D): one‐way ANOVA combined with Bonferroni post hoc test. For panel (Q): unpaired, two‐tailed student's t ‐test (differences between control and NPY groups for Rpl30 ) or two‐way ANOVA combined with Bonferroni post hoc test (differences among other groups for Tead1 or Junb ). * P < 0.05, ** P < 0.01, *** P < 0.001.
Recombinant Npy Protein, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant npy protein/product/MedChemExpress
Average 90 stars, based on 1 article reviews
recombinant npy protein - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

95
Cell Signaling Technology Inc atrial natriuretic peptide anp
Osteocyte <t>NPY‐induced</t> BMSC fate switching is mediated by the inhibition of TEAD1 and JUNB through cAMP/PKA/CREB signaling. qRT‐PCR analysis of Tead1 and Junb expression in BMSCs receiving different treatments under A) osteogenic or B) adipogenic induction for 24 h, or C) in undifferentiated BMSCs with different treatments for 24 h. n = 3 per group. D) qRT‐PCR and E) western blotting confirmed the overexpression efficiency of <t>recombinant</t> Tead1 and Junb lentiviruses in BMSCs. n = 3 per group. F) ARS and ORO staining images and G) quantification of the positively stained areas showing the reduced activity of NPY to inhibit osteogenesis and promote adipogenesis of BMSCs overexpressing Tead1 or Junb . Scale bar: 50 µm. n = 3 per group. ELISA for cAMP in BMSCs receiving different treatments under H) osteogenic or I) adipogenic induction for 24 h. n = 3 per group. PKA activity assay for cell homogenates of BMSCs receiving different treatments under J) osteogenic or K) adipogenic induction for 24 h. n = 3 per group. L) Western blotting for CREB and phosphorylated CREB (p‐CREB) in BMSCs receiving different treatments under osteogenic or adipogenic induction for 24 h. qRT‐PCR analysis of M) Tead1 and N) Junb expression in BMSCs receiving different treatments under osteogenic induction for 24 h. n = 3 per group. O) ARS and ORO staining images and P) quantification of the positively stained areas in BMSCs receiving different treatments under osteogenic or adipogenic induction. Scale bar: 50 µm. n = 3 per group. Q) ChIP‐qRT‐PCR analysis shows enrichment of the CREB antibody (CREB Ab)‐immunoprecipitated Tead1 or Junb promoter region relative to the input DNA. Normal rabbit anti‐IgG served as a negative control. Histone H3 antibody (Histone H3 Ab) pulldown for the enrichment of Rpl30 gene served as a positive control. n = 3 per group. Data are presented as mean ± SD. For panels (A), (B), (G), (H–K), (M), (N), and (P): unpaired, two‐tailed student's t ‐test (differences between un‐induced and control groups in (A), (B), and (H–K), or between control and NPY groups in (G), (M), (N), and (P)) or one‐way ANOVA combined with Bonferroni post hoc test (differences among other groups except un‐induced group in (A), (B), and (H–K), or except control group in (M), (N), and (P)). For panel (C) and (D): one‐way ANOVA combined with Bonferroni post hoc test. For panel (Q): unpaired, two‐tailed student's t ‐test (differences between control and NPY groups for Rpl30 ) or two‐way ANOVA combined with Bonferroni post hoc test (differences among other groups for Tead1 or Junb ). * P < 0.05, ** P < 0.01, *** P < 0.001.
Atrial Natriuretic Peptide Anp, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/atrial natriuretic peptide anp/product/Cell Signaling Technology Inc
Average 95 stars, based on 1 article reviews
atrial natriuretic peptide anp - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier

93
Boster Bio rabbit anti neuropeptide y polyclonal antibody
Osteocyte <t>NPY‐induced</t> BMSC fate switching is mediated by the inhibition of TEAD1 and JUNB through cAMP/PKA/CREB signaling. qRT‐PCR analysis of Tead1 and Junb expression in BMSCs receiving different treatments under A) osteogenic or B) adipogenic induction for 24 h, or C) in undifferentiated BMSCs with different treatments for 24 h. n = 3 per group. D) qRT‐PCR and E) western blotting confirmed the overexpression efficiency of <t>recombinant</t> Tead1 and Junb lentiviruses in BMSCs. n = 3 per group. F) ARS and ORO staining images and G) quantification of the positively stained areas showing the reduced activity of NPY to inhibit osteogenesis and promote adipogenesis of BMSCs overexpressing Tead1 or Junb . Scale bar: 50 µm. n = 3 per group. ELISA for cAMP in BMSCs receiving different treatments under H) osteogenic or I) adipogenic induction for 24 h. n = 3 per group. PKA activity assay for cell homogenates of BMSCs receiving different treatments under J) osteogenic or K) adipogenic induction for 24 h. n = 3 per group. L) Western blotting for CREB and phosphorylated CREB (p‐CREB) in BMSCs receiving different treatments under osteogenic or adipogenic induction for 24 h. qRT‐PCR analysis of M) Tead1 and N) Junb expression in BMSCs receiving different treatments under osteogenic induction for 24 h. n = 3 per group. O) ARS and ORO staining images and P) quantification of the positively stained areas in BMSCs receiving different treatments under osteogenic or adipogenic induction. Scale bar: 50 µm. n = 3 per group. Q) ChIP‐qRT‐PCR analysis shows enrichment of the CREB antibody (CREB Ab)‐immunoprecipitated Tead1 or Junb promoter region relative to the input DNA. Normal rabbit anti‐IgG served as a negative control. Histone H3 antibody (Histone H3 Ab) pulldown for the enrichment of Rpl30 gene served as a positive control. n = 3 per group. Data are presented as mean ± SD. For panels (A), (B), (G), (H–K), (M), (N), and (P): unpaired, two‐tailed student's t ‐test (differences between un‐induced and control groups in (A), (B), and (H–K), or between control and NPY groups in (G), (M), (N), and (P)) or one‐way ANOVA combined with Bonferroni post hoc test (differences among other groups except un‐induced group in (A), (B), and (H–K), or except control group in (M), (N), and (P)). For panel (C) and (D): one‐way ANOVA combined with Bonferroni post hoc test. For panel (Q): unpaired, two‐tailed student's t ‐test (differences between control and NPY groups for Rpl30 ) or two‐way ANOVA combined with Bonferroni post hoc test (differences among other groups for Tead1 or Junb ). * P < 0.05, ** P < 0.01, *** P < 0.001.
Rabbit Anti Neuropeptide Y Polyclonal Antibody, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti neuropeptide y polyclonal antibody/product/Boster Bio
Average 93 stars, based on 1 article reviews
rabbit anti neuropeptide y polyclonal antibody - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

Image Search Results


Fig. 6 An increase in levels of acetyl-CoA and H3K27ac promotes CXCL5 secretion in CAFs. The effects of acetate treatment on acetyl-CoA levels in LX-2 cells incubated with ExoHCT116 (A) and ExoSW480 (B). Western blot showed the effects of acetate treatment on CXCL5 and H3K27ac levels in LX-2 cells incubated with ExoHCT116 (C) and ExoSW480 (D). E The effects of Trichostatin A (TSA) treatment on CXCL5 and H3K27ac levels in LX-2 cells incubated with ExoHCT116 KD and their relative control. F The effects of C646 treatment on CXCL5 and H3K27ac levels in LX-2 cells incubated with ExoSW480 OE and their relative control. G, H Chromatin immunoprecipitation (ChIP) assays using IgG as a control were performed with antibody against H3K23ac. Examination of H3K27 acetylation status in CXCL5 gene promoter region in LX-2 cells incubated with ExoHCT116 KD and ExoHCT116 KD Ctrl or in LX-2 cells incubated with ExoHCT116 KD and ExoHCT116 KD Ctrl and treated with TSA (G). Examination of H3K27 acetylation status in CXCL5 gene promoter region in LX-2 cells incubated with ExoSW480 OE and ExoSW480 OE Ctrl or in LX- 2 cells incubated with ExoSW480 OE and ExoSW480 OE Ctrl and treated with C646 (H). Each experiment was performed in triplicate. Data are shown as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.

Journal: Cell death & disease

Article Title: Cancer-derived exosomal HSPC111 promotes colorectal cancer liver metastasis by reprogramming lipid metabolism in cancer-associated fibroblasts.

doi: 10.1038/s41419-022-04506-4

Figure Lengend Snippet: Fig. 6 An increase in levels of acetyl-CoA and H3K27ac promotes CXCL5 secretion in CAFs. The effects of acetate treatment on acetyl-CoA levels in LX-2 cells incubated with ExoHCT116 (A) and ExoSW480 (B). Western blot showed the effects of acetate treatment on CXCL5 and H3K27ac levels in LX-2 cells incubated with ExoHCT116 (C) and ExoSW480 (D). E The effects of Trichostatin A (TSA) treatment on CXCL5 and H3K27ac levels in LX-2 cells incubated with ExoHCT116 KD and their relative control. F The effects of C646 treatment on CXCL5 and H3K27ac levels in LX-2 cells incubated with ExoSW480 OE and their relative control. G, H Chromatin immunoprecipitation (ChIP) assays using IgG as a control were performed with antibody against H3K23ac. Examination of H3K27 acetylation status in CXCL5 gene promoter region in LX-2 cells incubated with ExoHCT116 KD and ExoHCT116 KD Ctrl or in LX-2 cells incubated with ExoHCT116 KD and ExoHCT116 KD Ctrl and treated with TSA (G). Examination of H3K27 acetylation status in CXCL5 gene promoter region in LX-2 cells incubated with ExoSW480 OE and ExoSW480 OE Ctrl or in LX- 2 cells incubated with ExoSW480 OE and ExoSW480 OE Ctrl and treated with C646 (H). Each experiment was performed in triplicate. Data are shown as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.

Article Snippet: Cells were cultured in the presence of appropriate exosomes (20μg/mL) for 48 h before supernatants were collected, and the CXCL5 level was detected by CXCL5 ELISA kit (EK0728, BOSTER) according to the manufacturer’s protocols.

Techniques: Incubation, Western Blot, Control, Chromatin Immunoprecipitation

Fig. 8 A schematic diagram of mechanism of exosomal HSPC111 facilitates CRLM via reprogramming lipid metabolism in CAFs. Exosomal HSPC111 derived from CRC cells phosphorylates ACLY in CAFs, leading to the increased levels of acetyl-CoA and histone acetylation to secrete CXCL5, and resulting in CRC cells colonized in liver via the CXCL5-CXCR2 axis.

Journal: Cell death & disease

Article Title: Cancer-derived exosomal HSPC111 promotes colorectal cancer liver metastasis by reprogramming lipid metabolism in cancer-associated fibroblasts.

doi: 10.1038/s41419-022-04506-4

Figure Lengend Snippet: Fig. 8 A schematic diagram of mechanism of exosomal HSPC111 facilitates CRLM via reprogramming lipid metabolism in CAFs. Exosomal HSPC111 derived from CRC cells phosphorylates ACLY in CAFs, leading to the increased levels of acetyl-CoA and histone acetylation to secrete CXCL5, and resulting in CRC cells colonized in liver via the CXCL5-CXCR2 axis.

Article Snippet: Cells were cultured in the presence of appropriate exosomes (20μg/mL) for 48 h before supernatants were collected, and the CXCL5 level was detected by CXCL5 ELISA kit (EK0728, BOSTER) according to the manufacturer’s protocols.

Techniques: Derivative Assay

Osteocyte NPY‐induced BMSC fate switching is mediated by the inhibition of TEAD1 and JUNB through cAMP/PKA/CREB signaling. qRT‐PCR analysis of Tead1 and Junb expression in BMSCs receiving different treatments under A) osteogenic or B) adipogenic induction for 24 h, or C) in undifferentiated BMSCs with different treatments for 24 h. n = 3 per group. D) qRT‐PCR and E) western blotting confirmed the overexpression efficiency of recombinant Tead1 and Junb lentiviruses in BMSCs. n = 3 per group. F) ARS and ORO staining images and G) quantification of the positively stained areas showing the reduced activity of NPY to inhibit osteogenesis and promote adipogenesis of BMSCs overexpressing Tead1 or Junb . Scale bar: 50 µm. n = 3 per group. ELISA for cAMP in BMSCs receiving different treatments under H) osteogenic or I) adipogenic induction for 24 h. n = 3 per group. PKA activity assay for cell homogenates of BMSCs receiving different treatments under J) osteogenic or K) adipogenic induction for 24 h. n = 3 per group. L) Western blotting for CREB and phosphorylated CREB (p‐CREB) in BMSCs receiving different treatments under osteogenic or adipogenic induction for 24 h. qRT‐PCR analysis of M) Tead1 and N) Junb expression in BMSCs receiving different treatments under osteogenic induction for 24 h. n = 3 per group. O) ARS and ORO staining images and P) quantification of the positively stained areas in BMSCs receiving different treatments under osteogenic or adipogenic induction. Scale bar: 50 µm. n = 3 per group. Q) ChIP‐qRT‐PCR analysis shows enrichment of the CREB antibody (CREB Ab)‐immunoprecipitated Tead1 or Junb promoter region relative to the input DNA. Normal rabbit anti‐IgG served as a negative control. Histone H3 antibody (Histone H3 Ab) pulldown for the enrichment of Rpl30 gene served as a positive control. n = 3 per group. Data are presented as mean ± SD. For panels (A), (B), (G), (H–K), (M), (N), and (P): unpaired, two‐tailed student's t ‐test (differences between un‐induced and control groups in (A), (B), and (H–K), or between control and NPY groups in (G), (M), (N), and (P)) or one‐way ANOVA combined with Bonferroni post hoc test (differences among other groups except un‐induced group in (A), (B), and (H–K), or except control group in (M), (N), and (P)). For panel (C) and (D): one‐way ANOVA combined with Bonferroni post hoc test. For panel (Q): unpaired, two‐tailed student's t ‐test (differences between control and NPY groups for Rpl30 ) or two‐way ANOVA combined with Bonferroni post hoc test (differences among other groups for Tead1 or Junb ). * P < 0.05, ** P < 0.01, *** P < 0.001.

Journal: Advanced Science

Article Title: Neuronal Induction of Bone‐Fat Imbalance through Osteocyte Neuropeptide Y

doi: 10.1002/advs.202100808

Figure Lengend Snippet: Osteocyte NPY‐induced BMSC fate switching is mediated by the inhibition of TEAD1 and JUNB through cAMP/PKA/CREB signaling. qRT‐PCR analysis of Tead1 and Junb expression in BMSCs receiving different treatments under A) osteogenic or B) adipogenic induction for 24 h, or C) in undifferentiated BMSCs with different treatments for 24 h. n = 3 per group. D) qRT‐PCR and E) western blotting confirmed the overexpression efficiency of recombinant Tead1 and Junb lentiviruses in BMSCs. n = 3 per group. F) ARS and ORO staining images and G) quantification of the positively stained areas showing the reduced activity of NPY to inhibit osteogenesis and promote adipogenesis of BMSCs overexpressing Tead1 or Junb . Scale bar: 50 µm. n = 3 per group. ELISA for cAMP in BMSCs receiving different treatments under H) osteogenic or I) adipogenic induction for 24 h. n = 3 per group. PKA activity assay for cell homogenates of BMSCs receiving different treatments under J) osteogenic or K) adipogenic induction for 24 h. n = 3 per group. L) Western blotting for CREB and phosphorylated CREB (p‐CREB) in BMSCs receiving different treatments under osteogenic or adipogenic induction for 24 h. qRT‐PCR analysis of M) Tead1 and N) Junb expression in BMSCs receiving different treatments under osteogenic induction for 24 h. n = 3 per group. O) ARS and ORO staining images and P) quantification of the positively stained areas in BMSCs receiving different treatments under osteogenic or adipogenic induction. Scale bar: 50 µm. n = 3 per group. Q) ChIP‐qRT‐PCR analysis shows enrichment of the CREB antibody (CREB Ab)‐immunoprecipitated Tead1 or Junb promoter region relative to the input DNA. Normal rabbit anti‐IgG served as a negative control. Histone H3 antibody (Histone H3 Ab) pulldown for the enrichment of Rpl30 gene served as a positive control. n = 3 per group. Data are presented as mean ± SD. For panels (A), (B), (G), (H–K), (M), (N), and (P): unpaired, two‐tailed student's t ‐test (differences between un‐induced and control groups in (A), (B), and (H–K), or between control and NPY groups in (G), (M), (N), and (P)) or one‐way ANOVA combined with Bonferroni post hoc test (differences among other groups except un‐induced group in (A), (B), and (H–K), or except control group in (M), (N), and (P)). For panel (C) and (D): one‐way ANOVA combined with Bonferroni post hoc test. For panel (Q): unpaired, two‐tailed student's t ‐test (differences between control and NPY groups for Rpl30 ) or two‐way ANOVA combined with Bonferroni post hoc test (differences among other groups for Tead1 or Junb ). * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: 24 h later, the culture medium was replaced with fresh osteogenic or adipogenic medium (Cyagen) supplemented with OCY‐CM (300 μg mL −1 at the protein level) from different groups, recombinant NPY protein (0.1 n m ; MedChemExpress), BIBO3304 (0.1 n m ; Selleck Chemicals, Houston, USA), NPY (0.1 n m ) + db‐cAMP (10 μ m ; MedChemExpress), NPY (0.1 n m ) + H‐89 (10 μ m ; MedChemExpress), NE (0.1 n m ; Sigma‐Aldrich), ACh (0.1 n m ; Sigma‐Aldrich), or an equal volume of vehicle.

Techniques: Inhibition, Quantitative RT-PCR, Expressing, Western Blot, Over Expression, Recombinant, Staining, Activity Assay, Enzyme-linked Immunosorbent Assay, Immunoprecipitation, Negative Control, Positive Control, Two Tailed Test, Control